NCT04186845 2025-09-22
Imaging Study to Investigate Safety and Diagnostic Performance of 18F rhPSMA 7.3 PET Ligand in Suspected Prostate Cancer Recurrence
Blue Earth Diagnostics
Phase 3 Completed
Clinical Trials
6 trialsNCT04410133 2025-08-28
REVELATE
Blue Earth Diagnostics
Phase 3 Completed
NCT04186819 2025-02-26
Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer.
Blue Earth Diagnostics
Phase 3 Completed
NCT03335059 2020-04-15
RITE-USA
Medical Enterprises Ltd.
Phase 3 Terminated
NCT00126412 2019-05-31
Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or Neuroblastoma
GE Healthcare
Phase 3 Completed
NCT01476774 2015-07-08
NORSPAN Transdermal Patches Phase III Study In Non-Cancer Pain
Mundipharma (China) Pharmaceutical Co. Ltd
Phase 3 Completed